Shuttle Pharma Soars 7.47% on Prostate Cancer Breakthrough

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) saw a significant pre-market rise of 7.47% on April 11, 2025, driven by the company's recent advancements in prostate cancer diagnostics and therapeutics.

Shuttle Pharma has filed a key provisional patent application with the USPTO for "PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy." This development is part of the company's Diagnostic subsidiary's efforts to create highly specific and effective theranostic agents for metastatic castration-resistant prostate cancer. The patent application leverages the high expression of PSMA on prostate cancer cells for accurate imaging and targeted therapy delivery using radio-labeled PSMA ligands.

The collaboration with Dr. Alan Kozikowski, a renowned medicinal chemist, has been instrumental in this advancement. Dr. Kozikowski's research, conducted in collaboration with Professor Joseph Neale at Georgetown University Medical Center, has contributed to the creation of both Pylarify and Pluvitco. This is the second patent application resulting from that project, highlighting the potential of targeting cellular antigens using antibody-drug-conjugates (ADCs) for more efficient drug delivery in prostate cancer treatment.

Shuttle Diagnostics, a wholly-owned subsidiary of Shuttle Pharma, is focused on developing pretreatment diagnostic blood tests for prostate cancer patients. The current focus includes the PSMA-B ligand and the PC-Rad test for predicting outcomes following radiation therapy for localized prostate cancer. There are currently no available tests on the market that are predictive of success for a specific treatment, making Shuttle Pharma's developments particularly significant.

Anatoly Dritschilo, MD, Shuttle Pharma’s Chairman and Chief Scientific Officer, commented on the potential of PSMA ligands for prostate cancer diagnosis and treatment. The company's scientists have collaborated with Dr. Kozikowski on discovery projects for radiation-sensitizing drugs and novel PSMA ligands, aiming to target prostate cancer cells preferentially to the effects of radiation and chemotherapeutic agents. This advancement could play a significant role in the future diagnosis and treatment of prostate cancer.